Published in J Hepatol on July 17, 2010
SLC40A1-R178G mutation and ferroportin disease. J Hepatol (2011) 1.97
Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci (2011) 1.50
Molecular diagnostic and pathogenesis of hereditary hemochromatosis. Int J Mol Sci (2012) 1.22
Non-HFE hemochromatosis. Rev Bras Hematol Hemoter (2012) 0.95
Ironing out Ferroportin. Cell Metab (2015) 0.90
EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet (2015) 0.81
Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis. BMC Med Genet (2012) 0.80
Ceruloplasmin-ferroportin system of iron traffic in vertebrates. World J Biol Chem (2014) 0.80
Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Front Pharmacol (2016) 0.78
"Pumping iron"-how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch (2017) 0.75
Pediatric Ferroportin Disease. J Pediatr Gastroenterol Nutr (2016) 0.75
Ferroportin-related haemochromatosis associated with novel Y64H mutation of the SCL40A1 gene. Prz Gastroenterol (2014) 0.75
Human macrophage ferroportin biology and the basis for the Ferroportin Disease. Hepatology (2016) 0.75
Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing. Blood Transfus (2016) 0.75
The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. Genet Med (2015) 0.75
Type 4B hereditary hemochromatosis associated with a novel mutation in the SLC40A1 gene: A case report and a review of the literature. Medicine (Baltimore) (2017) 0.75
Iron overload and altered iron metabolism in ovarian cancer. Biol Chem (2017) 0.75
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Human non-synonymous SNPs: server and survey. Nucleic Acids Res (2002) 50.45
Prediction of deleterious human alleles. Hum Mol Genet (2001) 21.00
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem (2000) 8.52
Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem (2000) 8.39
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature (2000) 7.46
Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med (2008) 5.43
A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell (2000) 5.31
A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem (2000) 5.21
A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet (2007) 5.17
The ferroportin disease. Blood Cells Mol Dis (2004) 2.90
Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest (2001) 2.49
Retracted The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab (2008) 2.25
Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics (2004) 2.21
The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A (2004) 2.18
ER stress controls iron metabolism through induction of hepcidin. Science (2009) 2.18
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood (2005) 2.02
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood (2005) 1.96
Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med (1999) 1.92
A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet (2001) 1.83
Iron overload in the Asian community. Blood (2009) 1.59
Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol (2005) 1.54
The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood (2009) 1.51
Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood (2003) 1.46
Hemochromatosis mutations in the general population: iron overload progression rate. Blood (2003) 1.43
Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood (2002) 1.42
Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol (2002) 1.32
A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood (2002) 1.31
Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis (2005) 1.30
Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis (2003) 1.29
Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis (2003) 1.24
Molecular and clinical correlates in iron overload associated with mutations in ferroportin. Haematologica (2006) 1.23
Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis (2007) 1.20
Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. J Mol Biol (2009) 1.18
Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics. Blood Cells Mol Dis (2003) 1.10
Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology (2002) 1.10
A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient. Gut (2003) 1.08
Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol (2005) 1.07
Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood (2009) 1.04
Common genetic variants of the ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women. BMC Med Genet (2009) 1.03
Integration of genome data and protein structures: prediction of protein folds, protein interactions and "molecular phenotypes" of single nucleotide polymorphisms. Curr Opin Struct Biol (2001) 1.02
Hepatic iron concentration, fibrosis and response to venesection associated with the A77D and V162del "loss of function" mutations in ferroportin disease. Blood Cells Mol Dis (2007) 1.01
Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol Cell Physiol (2009) 1.01
Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica (2003) 1.01
Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol (2003) 1.00
Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology (2005) 0.95
Rare causes of hereditary iron overload. Semin Hematol (2002) 0.94
Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells Mol Dis (2006) 0.94
Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol (2005) 0.93
Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations. J Hepatol (2008) 0.92
Lack of enterocyte iron accumulation in the ferroportin disease. Blood Cells Mol Dis (2005) 0.90
Hemochromatosis with mutation of the ferroportin 1 (IREG1) gene. Intern Med (2005) 0.89
Identification of ferroportin disease in the Indian subcontinent. Gut (2005) 0.88
Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet (2004) 0.88
Hemochromatosis: genetic testing and clinical practice. Clin Gastroenterol Hepatol (2005) 0.88
Human mutation D157G in ferroportin leads to hepcidin-independent binding of Jak2 and ferroportin down-regulation. Blood (2010) 0.87
The impact of the mutations of the HFE gene and of the SLC11A3 gene on iron overload in Greek thalassemia intermedia and beta(s)/beta(thal) anemia patients. Haematologica (2004) 0.86
A novel mutation in ferroportin implicated in iron overload. J Hepatol (2007) 0.85
Disease progression and liver cancer in the ferroportin disease. Gut (2007) 0.85
SLC40A1 c.1402G-->a results in aberrant splicing, ferroportin truncation after glycine 330, and an autosomal dominant hemochromatosis phenotype. Acta Haematol (2007) 0.85
A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med (2005) 0.84
Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. Clin Genet (2007) 0.84
Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV. Blood Cells Mol Dis (2007) 0.83
Global sequencing approach for characterizing the molecular background of hereditary iron disorders. Clin Chem (2007) 0.83
Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. Blood Cells Mol Dis (2005) 0.82
Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. Hepatology (2010) 0.82
Multi-organ iron overload in an African-American man with ALAS2 R452S and SLC40A1 R561G. Acta Haematol (2008) 0.80
Ferroportin disease due to the A77D mutation in Australia. Gut (2005) 0.80
A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol (2009) 0.79
A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis. Blood Cells Mol Dis (2005) 0.79
The hemochromatosis N144H mutation of SLC11A3 gene in patients with type 2 diabetes. Mol Genet Metab (2002) 0.79
Identification and in silico analysis of 14 novel GJB1, MPZ and PMP22 gene mutations. Eur J Hum Genet (2009) 0.78
Mutation analysis of hepcidin and ferroportin genes in Italian prospective blood donors with iron overload. Am J Hematol (2009) 0.77
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet (2009) 4.84
Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet (2007) 3.94
Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation. Am J Hum Genet (2004) 2.99
Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 2.80
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet (2005) 2.63
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
Autocrine formation of hepcidin induces iron retention in human monocytes. Blood (2007) 2.50
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. Nat Genet (2008) 2.24
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist (2009) 2.23
ER stress controls iron metabolism through induction of hepcidin. Science (2009) 2.18
Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain (2011) 2.15
Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl (2013) 2.09
Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology (2007) 2.09
Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl (2003) 2.04
Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology (2011) 2.02
Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2007) 2.00
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Mutations in PYCR1 cause cutis laxa with progeroid features. Nat Genet (2009) 1.89
Echinococcosis of the liver. Abdom Imaging (2008) 1.88
Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat Genet (2012) 1.85
Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology (2013) 1.77
Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol (2005) 1.76
Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transpl (2004) 1.70
Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol (2013) 1.70
Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol (2002) 1.65
TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. Am J Hum Genet (2011) 1.65
Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation. Liver Transpl (2006) 1.60
Huh-7: a human "hemochromatotic" cell line. Hepatology (2010) 1.51
Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Gastroenterology (2009) 1.51
Hepcidin expression does not rescue the iron-poor phenotype of Kupffer cells in Hfe-null mice after liver transplantation. Gastroenterology (2010) 1.46
Pretransplantation evaluation of the cirrhotic liver with explantation correlation: accuracy of CT arterioportography and digital subtraction hepatic angiography in revealing hepatocellular carcinoma. AJR Am J Roentgenol (2003) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology (2012) 1.45
Loss of dermatan-4-sulfotransferase 1 (D4ST1/CHST14) function represents the first dermatan sulfate biosynthesis defect, "dermatan sulfate-deficient adducted thumb-clubfoot syndrome". Hum Mutat (2011) 1.44
Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome--an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13. Am J Hum Genet (2008) 1.43
Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I. Am J Hum Genet (2010) 1.42
Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function. Am J Pathol (2011) 1.41
Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol (2006) 1.36
The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. J Hepatol (2003) 1.36
Late-onset Wilson's disease. Gastroenterology (2007) 1.30
Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis (2003) 1.29
Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle. Hum Mol Genet (2005) 1.26
Molecular and clinical correlates in iron overload associated with mutations in ferroportin. Haematologica (2006) 1.23
BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology (2010) 1.22
Loss-of-function of MYO5B is the main cause of microvillus inclusion disease: 15 novel mutations and a CaCo-2 RNAi cell model. Hum Mutat (2010) 1.20
Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol (2005) 1.17
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
Mutations in the gene encoding IFT dynein complex component WDR34 cause Jeune asphyxiating thoracic dystrophy. Am J Hum Genet (2013) 1.16
Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea. Am J Hum Genet (2009) 1.15
Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist (2011) 1.14
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2012) 1.14
Clinical and electrophysiological features in Charcot-Marie-Tooth disease with mutations in the NEFL gene. Arch Neurol (2007) 1.12
The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med (2002) 1.11
Mutations in GDF5 reveal a key residue mediating BMP inhibition by NOGGIN. PLoS Genet (2009) 1.09
Loss of dermatan-4-sulfotransferase 1 function results in adducted thumb-clubfoot syndrome. Am J Hum Genet (2009) 1.09
Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology (2009) 1.08
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol (2009) 1.07
Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: molecular and cellular aspects. Matrix Biol (2002) 1.06
Image of the month. Jejunal diverticular perforation secondary to delayed distal migration of biliary endoprosthesis. Arch Surg (2011) 1.06
Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology (2005) 1.06
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology (2009) 1.05
Further evidence for genetic heterogeneity of distal HMN type V, CMT2 with predominant hand involvement and Silver syndrome. J Neurol Sci (2007) 1.04
Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol (2009) 1.03
Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol (2013) 1.02
Inherited ichthyoses/generalized Mendelian disorders of cornification. Eur J Hum Genet (2012) 1.02
The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol (2005) 1.01
In vitro analysis of LIPH mutations causing hypotrichosis simplex: evidence confirming the role of lipase H and lysophosphatidic acid in hair growth. J Invest Dermatol (2009) 1.00
Filaggrin mutations p.R501X and c.2282del4 in ichthyosis vulgaris. Eur J Hum Genet (2006) 0.99
Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch (2004) 0.99
Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl (2013) 0.98
Ferroportin is a monomer in vivo in mice. Blood Cells Mol Dis (2005) 0.98
Microvillus inclusion disease: loss of Myosin vb disrupts intracellular traffic and cell polarity. Traffic (2013) 0.98
High incidence of recurrent copy number variants in patients with isolated and syndromic Müllerian aplasia. J Med Genet (2011) 0.98
Mutation of POC1B in a severe syndromic retinal ciliopathy. Hum Mutat (2014) 0.97
The canine copper toxicosis gene MURR1 does not cause non-Wilsonian hepatic copper toxicosis. J Hepatol (2003) 0.97
Iron in NASH, chronic liver diseases and HCC: how much iron is too much? J Hepatol (2008) 0.97
Genetic characterization of congenital tufting enteropathy: epcam associated phenotype and involvement of SPINT2 in the syndromic form. Hum Genet (2013) 0.96
Cardiac hepatopathy before and after heart transplantation. Transpl Int (2005) 0.96
Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol (2007) 0.95
Defining the phenotype in congenital disorder of glycosylation due to ALG1 mutations. Pediatrics (2012) 0.95
Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology (2005) 0.95
Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant (2009) 0.93
Altered hepatic BMP signaling pathway in human HFE hemochromatosis. Blood Cells Mol Dis (2010) 0.93
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Evidence for genetic heterogeneity in lymphedema-cholestasis syndrome. J Pediatr (2003) 0.93
Iron supplementation in athletes--first do no harm. Nutrition (2004) 0.92
Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol (2008) 0.92
A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. Eur Radiol (2012) 0.92
Haptoglobin modifies the hemochromatosis phenotype in mice. Blood (2004) 0.91
A distinctive gene expression fingerprint in mentally retarded male patients reflects disease-causing defects in the histone demethylase KDM5C. Pathogenetics (2010) 0.91